Pulmonx (LUNG) vs Neuronetics (STIM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pulmonx (LUNG) has outperformed Neuronetics (STIM) over the past year, gaining 78.5% versus a loss of 4.6%. Over five years, STIM leads with a -69.7% price change compared with -92.4% for LUNG. Neuronetics is the larger company by market cap ($120.6 million vs $111.9 million), about 1.1 times the size.
Neuronetics converts more of its revenue into profit, with a net margin of -26.1% versus -59.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LUNG | STIM |
|---|---|---|
| Share price | $2.57 | $1.25 |
| Market cap | $111.93M | $120.60M |
| 1-day change | -6.20% | +0.81% |
| YTD return | +16.29% | -9.42% |
| 1-year return | +78.47% | -4.58% |
| 5-year return | -92.39% | -69.66% |
| EPS (TTM) | $-1.01 | $-0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $90.50M | $149.16M |
| Revenue growth (YoY) | +8.01% | +99.17% |
| Net income (latest FY) | $-54.00M | $-39.00M |
| Gross margin | 74.19% | 48.48% |
| Operating margin | -59.30% | -21.08% |
| Net margin | -59.67% | -26.15% |
| 52-week high | $3.25 | $3.44 |
| 52-week low | $1.13 | $0.80 |
| Distance from 52-week high | -20.92% | -63.66% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +65.37% | +380.00% |
| Average volume | 641.52K | 1.76M |
| Shares outstanding | 43.55M | 96.48M |
| Employees | 296 | 658 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LUNG has outperformed STIM by 83.1 percentage points over the past year.
- Neuronetics is more profitable, keeping -26.1 cents of every revenue dollar as net income versus -59.7 cents for Pulmonx.
- Neuronetics grew revenue faster in its latest fiscal year (+99.17% vs +8.01%).
About Pulmonx
LUNG stock →Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Health Care · Medical/Dental Instruments · 296 employees
About Neuronetics
STIM stock →Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 658 employees
LUNG vs STIM FAQ
Which is bigger, Pulmonx or Neuronetics?
Neuronetics (STIM) is larger, with a market capitalization of $120.60M compared with $111.93M for Pulmonx (LUNG).
Which stock has performed better over the past year, LUNG or STIM?
LUNG returned +78.47% over the past 12 months, compared with -4.58% for STIM (price return, excluding dividends). Past performance does not predict future results.
Are Pulmonx and Neuronetics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.